多西他赛联合希罗达和多西他赛联合顺铂治疗蒽环类耐药乳腺癌的临床疗效  

Efficacy of docetaxel combined with xeloda or cisplatin in treating anthracycline-resistant breast cancer

作　　者：彭兴梅[1] 李爱国[2] 杨爱红[1] 李君艳[1] 

机构地区：[1]新乡医学院第三附属医院肿瘤科,河南省453003 [2]新乡医学院第一附属医院骨科

出　　处：《江苏医药》2014年第13期1539-1541,共3页Jiangsu Medical Journal

摘　　要：目的观察TX方案(多西他赛+希罗达)和TP方案(多西他赛+顺铂)治疗蒽环类药物耐药乳腺癌的临床效果。方法蒽环类药物耐药的乳腺癌患者50例随机均分为TP方案化疗(A)组和TX方案化疗(B)组。观察两组患者的近期疗效、远期生存率和不良反应。结果治疗结束后2个月,A组完全缓解率为16.0%,客观有效率为60.0%,略高于B组的12.0%和56.0%(P>0.05)。随访3年。A组和B组的1、2和3年生存率相仿(62.5%vs.60.9%、37.5%vs.30.4%和20.8%vs.17.4%)(P>0.05)。两组不良反应主要表现为骨髓抑制、胃肠道反应和手足综合征,经对症治疗均好转。结论 TX方案和TP方案治疗蒽环类耐药乳腺癌均有良好疗效,不良反应可耐受。Objective To observe the clinical efficacy of TX regimen（docetaxel plus capecitabine）and TP regimen（docetaxel plus cisplatin）in the treatment of anthracycline-resistant breast cancer.Methods Fifty patients with anthracycline-resistant breast cancer were equally randomized into two groups of A（treated with TX regimen）and B（treated with TP regimen）.The short-term efficacy,long-term survival and adverse reaction were observed and compared.Results In2months after the end of treatment,the complete remission rate and objective response rate of group A were 16.0% and 60.0%,which were slightly higher than 12.0% and 56.0% of group B（P〉0.05）.The patients were followed up for 3years.The 1-,2-,and 3-year survival rates of group A were similar to those of group B（62.5% vs.60.9%,37.5% vs.30.4% and 20.8% vs.17.4%）（P〉0.05）.The main adverse reactions of two groups included bone marrow suppression,gastrointestinal side effects and hand-foot syndrome,which were disappeared or improved by symptomatic treatments.Conclusion Both of TX regimen and TP regimen produce a good efficacy in the treatment of anthracycline-resistant breast cancer.

关 键 词：乳腺癌 多西他赛 希罗达 顺铂 蒽环类 耐药性 

分 类 号：R737[医药卫生—肿瘤]